Drug Importation in Connecticut: An Overview
The Connecticut legislature has not yet advanced bills that have been introduced to legalized importation of drugs from Canada. However, in 2019 the state budgeted funds for the Department of Consumer Protection to hire a project manager to submit a request for approval for a Canadian Prescription Drug Importation Program to the federal Secretary of Health and Human Services.
Budget documents indicate that Connecticut will be submitting an importation plan to the Department of Health and Human Services in 2020 or 2021.
How should we evaluate this program?
The program hasn't started yet, or even been designed, so there's no way to measure whether it saved money or kept patients safe, both promises made at the time of passage. However, the 2003 Medicare Modernization Act contains requirements for safety requirements built into any such program.
Official actions and statements
Connecticut has made no official statements regarding importation.
Background / resources
Learn more about
- The Drug Importation Debate
- Fake Medicine in Connecticut
- The Importance of U.S. Closed Drug Supply Chain
Testimony Opposing Importation
- Testimony of Shabbir Imber Safdar, PSM Executive Director at Connecticut's Health Care Affordability Informational Forum, November 14, 2019
Op-eds from the Experts
This editorial by Wayne Winegarden, Ph.D. appeared in Forbes on August 7, 2019. Dr. Winegarden is the Managing Editor for EconoSTATS and a senior Fellow in Business and Economics at the Pacific Research Institute.
Policy Expert: “Even if Canada were a willing participant, the U.S. can’t ensure the safety of these drugs.”
In this July 31, 2019 blog post on the Citizens Against Government Waste (CAGW) website, CAGW Director of Health and Science Policy Elizabeth Wright questions the questions the effectiveness and safety of government importation schemes.
This editorial by Adam Fein and Dirk Rodgers was published in Stat News on July 11, 2019. In it, Fein and Rodgers warn that plans by states to create drug importation programs will open new pathways for counterfeit drugs to enter the U.S. drug supply chain…
Importation Is An Opportunity For Organized Crime to Expand Counterfeit Drug Profits, DEA Veteran Says
This editorial by retired DEA agent Douglas Hebert was published in The Arizona Capital Times ,on June 27, 2019. In it, Hebert explains how drug importation programs will help organized crime expand their $200 billion-a-year counterfeit pharmaceutical industry into the U.S., at the expense of Americans.
Retired Canadian law enforcement official urges the New York Legislature: “Step Away” from dangerous drug importation proposal
In this editorial, which was published in Crain’s New York Business on June 19, 2019, Canadian law enforcement veteran Don Bell explains that the New York Legislature’s effort to establish a wholesale prescription drug importation program, is “a gigantic loophole that criminals will pounce on to traffic counterfeit drugs into the state.”
In this editorial, which was published by the Fraser Institute on June 13, 2019, economist Dr. Kristina Acri argues against importation, concluding: “Diverting drugs meant for Canadian patients to the U.S. through state importation schemes will create shortages for Canadian patients and increase pressure on potentially unscrupulous suppliers to source drugs from wherever they can, opening the door to counterfeiters.”
This editorial by Guy Anthony was published in the Orlando Sentinel on June 12, 2019. Anthony, President and CEO of Black, Gifted & Whole, a nonprofit focused on issues surrounding black, queer men, warns that drug importation will open up “a market for dangerous, counterfeit drugs” that will make it harder for people to live with HIV and other complex illnesses.
Canadian Policy Researcher Warns That Importation Plans By U.S. States Would Leave Canada Without Crucial Medicines
This editorial by Nigel Rawson was published in The Hills Times on June 9, 2019. Dr. Rawson, president of Eastlake Research Group, a senior fellow at the Fraser Institute, and an affiliated scholar with the Canadian Health Policy Institute, warns that Canada would run out of necessary medicine if U.S. states begin drug importation programs…
Former DEA agent Doug Herber wrote this editorial, which was published on May 31, 2019 in the White Mountain Independent. In it, he writes that drug importation will cause “patients [to] unwittingly purchase foreign counterfeit drugs disguised as low-level medication, unaware of the dangers, end up as an overdose statistic. “